Calendar of Events Donate Now
Subscribe for Email Updates

    The CAN DO Program shed light on all of those things you don’t think to ask about, but that can make such a difference in your life.

    Jonna P., CAN DO & JUMPSTART Program Participant
    •  


    US FDA approves Extavia® – the first in a new portfolio of planned MS therapies from Novartis

    Posted Monday, August 17, 2009

    Novartis Pharmaceuticals Corporation
    One Health Plaza
    East Hanover, NJ 07936-1080
    http://www.us.novartis.com

    US FDA approves Extavia® – the first in a new portfolio of planned MS therapies from Novartis to help patients with this devastating disease

     Extavia is branded version of interferon beta-1b, a standard-of-care for multiple sclerosis in the US for more than 16 years1

    • MS affects around 400,000 people in US2 – one of the most common neurological disorders in young adults3

    • FDA approval marks important step forward for Novartis, laying foundation for innovative approach to treatment of MS

    East Hanover, NJ, August 17, 2009 – The US Food and Drug Administration (FDA) has approved Extavia® (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease.

    Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with the disease as shown by magnetic resonance imaging (MRI)4.

    The same medicinal product as Betaseron®*, Extavia offers patients and physicians a new branded version of interferon beta-1b, a first-line disease-modifying therapy that has been a standard-of-care for MS in the US for more than 16 years1. Extavia will be marketed by the Pharmaceuticals Division of Novartis.

    “Interferon is a mainstay of treatment in MS,” said Doug Jeffery, MD, Associate Professor at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, USA. “With the approval of Extavia, patients have another option with a well-established safety and efficacy profile to help manage this disease.”

    MS is estimated to affect approximately 400,000 patients in the US, of whom more than 80% have relapsing-remitting MS5. MS is one of the most common causes of neurological disability in young adults. It is a chronic autoimmune disease in which the body’s immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain6. The destruction of myelin causes problems with muscle control and strength, vision, balance, sensation and mental function7.

    “Novartis has been a leader in neuroscience for more than 50 years, having pioneered a number of breakthrough therapies which remain important treatments to this day,” said Joe Jimenez, CEO of the Novartis Pharmaceuticals Division. “We are committed to providing new approaches to MS care, and the FDA approval of Extavia marks the beginning of our long-term commitment to the MS community in the US.”

    Extavia will be available to patients in the US this fall. Along with their prescription for Extavia, patients will be given access to a support program including a nurse helpline, one-on-one injection training and reimbursement support services. Extavia patients will have an autoinjector available to them from Novartis. 

    “MS is unpredictable and can be difficult to manage,” said Aaron Miller, MD, Professor of Neurology at Mount Sinai School of Medicine in New York, USA. “Support programs are an essential element to help patients and physicians effectively manage this complicated disease.”

    MS typically presents in relapsing forms involving acute self-limiting attacks of neurological dysfunction (known as exacerbations or relapses), followed by complete or partial restoration of function6.

    Interferon beta-1b has been shown to reduce annualized relapse rates by 34% (p=0.0001)8, with patients nearly twice as likely to remain relapse-free for more than two years compared to those receiving placebo (31% vs. 16%, p=0.007)8. In addition, treatment with interferon beta-1b may slow disease progression9. After two years, almost three-quarters of patients who experienced a single episode of neurological disease lasting 24 hours or more did not progress to clinically definite MS10.

    In the European Union Extavia is available in 12 countries and is approved for relapsing-remitting MS as well as early MS (defined as a single demyelinating event with an active inflammatory process) and a steadily worsening form of the disease known as secondary progressive MS with relapses.

    Extavia should be used with caution in patients with depression. Injection site necrosis has been reported in 4% of patients in controlled trials. Typically, injection site necrosis occurs within the first four months of therapy. Necrosis may occur at a single injection site or multiple injection sites. Patient understanding and use of aseptic self-injection techniques and procedures should be periodically reevaluated, particularly if injection site necrosis has occurred. Anaphylaxis has been reported as a rare complication of interferon use. Other allergic reactions have included dyspnea, bronchospasm, tongue edema, skin rash, and urticaria.

    The rate of flu-like symptom complex was approximately 57% in the four controlled clinical trials. The incidence decreased over time, with only 10% of patients reporting flu-like symptom complex at the end of the studies. Monitoring of complete blood and differential white blood cell counts, platelet counts and blood chemistries, including liver function tests, are recommended at regular intervals.

    The most commonly reported adverse reactions are lymphopenia, injection site reaction, asthenia, flu-like symptom complex, headache and pain. Based on all the available evidence, the relationship between antibody formation and clinical safety and efficacy is not known. Female patients should be warned about the potential risk to pregnancy. The mechanism of action of interferon beta-1b in patients with multiple sclerosis is unknown. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. Patients should be advised of the importance of rotating injection sites.

    * Novartis gained the rights to seek approval for its own branded version of interferon beta-1b through agreements with Bayer Schering, the company that markets Betaseron.
    Betaseron is marketed under the name of Betaferon® outside the US. Betaseron and Betaferon are registered trademarks of Bayer Schering Pharma AG.

    Disclaimer
    The foregoing release contains forward-looking statements that can be identified by terminology such as “planned,” “may,” “committed,” “long-term commitment,” “will,” “can,” “likely,” or similar expressions, or by express or implied discussions regarding potential future multiple sclerosis products or regarding potential future revenues from Extavia or other multiple sclerosis products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any additional Novartis multiple sclerosis products will be approved for sale in any market. Nor can there be any guarantee that Extavia or such other products will achieve any particular levels of revenue in the future. In particular, management’s expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    About Novartis
    Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

    Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group’s continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

     References
    1 FDA approves Betaseron® for use after the first event suggestive of multiple sclerosis [press release]. Wayne, NJ: Berlex: 23 October 2006.
    2 National Multiple Sclerosis Society website: http://www.nationalmssociety.org/about-multiple-sclerosis. Accessed August 12, 2009.
    3 Multiple Sclerosis International Federation website. http://www.msif.org/en/about_ms/what_is_ms.html. Accessed August 12, 2009.
    4 Extavia Prescribing Information, August 14, 2009.
    5 Habermann, T. and Amit K. Ghosh ed. Mayo Clinic Internal Medicine Concise Textbook. Florence, KY: Informa HealthCare, 2007.
    6 National Multiple Sclerosis Society website. http://www.nationalmssociety.org. Accessed August 12, 2009.
    7 Multiple Sclerosis International Federation website. http://www.msif.org/en/about_ms/symptoms.html. Accessed August 12, 2009.
    8 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology. 1993;43:655-661.
    9 Betaseron (interferon beta-1b) Prescribing Information. Available online at http://berlex.bayerhealthcare.com/html/products/pi/Betaseron_PI.pdf. 10 Kappos L, Freedman MS, Polman CH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242-1249.

    # # #

    Novartis US Media Contacts

    Heather Rose
    Novartis Pharmaceuticals Corporation
    Phone: 862-778-1414
    Mobile: 917-859-4086
    Email : heather.rose@novartis.com 
    Anna Frable
    Novartis Pharmaceuticals Corporation
    862-778-5388 (office)
    732-673-5262 (mobile)
    anna.frable@novartis.com

    e-mail: media.relations@novartis.com


    Back to press release list
    100 W. Beaver Creek Blvd. Suite 200 PO Box 5860 Avon, CO 81620 Phone: 970-926-1290 or 800-367-3101 Fax: 970-926-1295 Email: info@mscando.org
    MS Coalition Charity Navigator Consortium of Multiple Sclerosis Centers Independent Charities of America Humane Charity

    Can Do Multiple Sclerosis™ is a 501 (c)(3) nonprofit organization.
    Charitable Organization Number: 74-2337853

    Formerly The Heuga Center for Multiple Sclerosis | Founded by Jimmie Heuga

    A national nonprofit organization, Can Do MS is a leading provider of innovative lifestyle empowerment programs
    that empower people with MS and their support partners to transform and improve their quality of life.

    Celebrate Can Do Day! Submit your can do Photo Pledge on our wall today! - Read More